Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of Regorafenib versus placebo as maintenance therapy in RAS wild-type metastatic colorectal cancer
2013-005428-41Phase 3Terminated
- Sponsor
- Department of Experimental and Clinical Medicine "F. Magrassi"
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Regorafenib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Oct 2014; status: terminated.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2013-005428-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005428-41.